RxDoctor Payments DataLook up a doctor →

Rohit Loomba, MD

Internal Medicine · la Jolla, CANPI 1578593521

Payments from drug & device makers

$15,105,123in general payments, 2019–2025

Across 954 payments — averaging $15,833 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$4.1M
  • Astrazeneca UK Limited$2.4M
  • Gilead$2.1M
  • Astrazeneca AB$2M
  • Pfizer$1.3M
  • Janssen Research & Development, LLC$837K
  • plus $2.4M from 44 others
$139,001in research payments, 2019–2025

Across 8 payments — averaging $17,375 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biomarin Pharmaceutical Inc.$134K
  • Novo Nordisk AS$3K
  • Eli Lilly$1K
  • Novartis$873

What the payments were for

  • Consulting fees$653,37668%
  • Speaking & faculty fees$111,47612%
  • Grants$69,8877%
  • Travel & lodging$119,96612%
  • Food & beverage$10,4721%
  • Education$310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS84$4,073,959
Astrazeneca UK Limited20$2,446,385
Gilead96$2,090,356
Astrazeneca AB4$1,968,297
Pfizer48$1,285,700
Janssen Research & Development, LLC19$836,731
Intercept Pharmaceuticals, Inc.88$515,931
Takeda Pharmaceuticals U.S.A., Inc.132$353,552
E.r. Squibb & Sons, L.L.C.22$314,498
Madrigal Pharmaceuticals77$194,520
Biomarin Pharmaceutical Inc.35$157,303
AbbVie(2 entities)42$131,091
Novo Nordisk44$114,697
Eli Lilly26$94,787
Boehringer Ingelheim32$88,464
GSK40$79,965
Theratechnologies Inc.11$68,181
AstraZeneca10$55,898
Genentech, Inc.2$39,213
Merck11$33,228
Kowa Research Institute, Inc.16$29,895
Novartis3$22,281
Ionis Pharmaceuticals, Inc.5$16,134
Siemens Medical Solutions USA, Inc.14$16,086
UCB SA2$14,000
Regeneron2$13,590
Bristol Myers Squibb1$8,875
Amgen(2 entities)7$8,246
Dr.reddy's Laboratories,inc.2$5,250
Mallinckrodt Enterprises LLC3$5,171
Boehringer Ingelheim International GmbH2$4,550
Mallinckrodt Hospital Products Inc.2$4,443
Boehringer Ingelheim RCV GmbH & Co KG14$4,190
Sanofi3$3,184
Cipla USA Inc.1$2,500
Ipsen Biopharmaceuticals, Inc1$1,660
KOWA Company, LTD.8$826
Boehringer Ingelheim Pharma GmbH & Co.kg9$433
Cook Medical LLC4$242
Regeneron Healthcare Solutions, Inc.1$122
Teva Pharmaceuticals USA, Inc.1$121
Pacira Therapeutics, Inc.1$117
Lilly USA, LLC1$114
Aurinia Pharma U.S., Inc.1$106
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$65
Daiichi Sankyo Inc.1$42
Micro-tech Endoscopy USA, Inc.1$39
Boston Scientific1$35
Fujifilm Healthcare Americas Corporation1$27
Olympus America Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,105,123 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$6,462
Medicare patients
36
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom53$206,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Madrigal PharmaceuticalsRezdiffra$194,520$206,06353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →